Llwytho...
Demonstration of safety of intravenous immunoglobulin in geriatric patients in a long-term, placebo-controlled study of Alzheimer's disease
INTRODUCTION: We present safety results from a study of Gammagard Liquid intravenous immunoglobulin (IGIV) in patients with probable Alzheimer's disease. METHODS: This was a placebo-controlled double-blind study. Subjects were randomized to 400 mg/kg (n = 127), 200 mg/kg (n = 135) IGIV, or to 0...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Alzheimers Dement (N Y) |
|---|---|
| Prif Awduron: | , , , , , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Elsevier
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5644268/ https://ncbi.nlm.nih.gov/pubmed/29067300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.trci.2016.06.003 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Llwytho...